← back to search

Yongqiang Liu

Guangzhou University of Chinese Medicine · CN
Area of research
Genetics · Cardiology and Cardiovascular Medicine
Research interest
Research focused on Apoptosis and Cancer research, with related work in In vivo, Microglia, Cloud computing. Notable publications include 'Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals', 'Pro-inflammatory and proliferative microglia drive progression of glioblastoma', and 'An integrated information system for snowmelt flood early-warning based on internet of things'.
h-index
citations
1,325
works
43
NIH funding
primary concept
email

Recent publications

Estimation of Moderate-Resolution Snow Depth in Xinjiang With Enhanced-Resolution Passive Microwave and Reanalysis Data by Machine Learning Methods
IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing 2025cited by 4position: middledoi
Proteomic screening identifies brusatol targets TGFβRII to suppresses non-small cell lung cancer metastasis
Phytomedicine 2025cited by 4position: lastdoi
Variation characteristics and influencing mechanisms of CO2 flux from grassland ecosystem in the Central Tianshan Mountains, China
Ecological Indicators 2025cited by 3position: lastdoi
A Physically Constrained Downscaling Framework for Hourly, All-Sky Land Surface Temperature in Mountainous Regions
IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing 2025cited by 3position: middledoi
Towards high-quality territorial spaces: Theorizing space quality and measuring its social-spatial inequities
Habitat International 2025cited by 3position: middledoi
High cellular plasticity state of medulloblastoma local recurrence and distant dissemination
Cell Reports Medicine 2025cited by 0position: middledoi
Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer
Cell Reports Medicine 2025cited by 0position: middledoi
Targeting Skp2 by camptothecin induces p27 accumulation and confers drug resistance in non-small cell lung cancer
European Journal of Pharmacology 2025cited by 0position: lastdoi
Single‐cell transcriptomic sequencing identifies subcutaneous patient‐derived xenograft recapitulated medulloblastoma
Animal Models and Experimental Medicine 2024cited by 4position: middledoi
Centipeda minima extracts and the active sesquiterpene lactones have therapeutic efficacy in non-small cell lung cancer by suppressing Skp2/p27 signaling pathway
Journal of Ethnopharmacology 2024cited by 4position: lastdoi
Flux Balance and Attribution Analysis of Co2 in Grassland Ecosystems in Xinjiang of China
SSRN Electronic Journal 2024cited by 0position: middledoi
Theories and practices of comprehensive land consolidation in promoting multifunctional land use
Habitat International 2023cited by 49position: firstdoi
Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer
British Journal of Pharmacology 2023cited by 8position: lastdoi
Ethanol Extract of <i>Citrus grandis</i> ‘Tomentosa’ Exerts Anticancer Effects by Targeting Skp2/p27 Pathway in Non‐Small Cell Lung Cancer
Molecular Nutrition & Food Research 2023cited by 5position: lastdoi
Corrigendum to: Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2
Acta Materia Medica 2023cited by 3position: lastdoi
Brusatol has therapeutic efficacy in non-small cell lung cancer by targeting Skp1 to inhibit cancer growth and metastasis
Pharmacological Research 2022cited by 40position: lastdoi
Promising anticancer activities and mechanisms of action of active compounds from the medicinal herb Centipeda minima (L.) A. Braun &amp; Asch
Phytomedicine 2022cited by 19position: firstdoi
Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2
Acta Materia Medica 2022cited by 18position: lastdoi
Adaptability of MODIS Daily Cloud-Free Snow Cover 500 m Dataset over China in Hutubi River Basin Based on Snowmelt Runoff Model
Sustainability 2022cited by 9position: middledoi
Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
Chinese Medicine 2022cited by 8position: middledoi
Synthesis of dihydrofuran-3-one and 9,10-phenanthrenequinone hybrid molecules and biological evaluation against colon cancer cells as selective Akt kinase inhibitors
Molecular Diversity 2022cited by 5position: middledoi
High-Resolution Inversion Method for the Snow Water Equivalent Based on the GF-3 Satellite and Optimized EQeau Model
Remote Sensing 2022cited by 2position: middledoi
Corrigendum to “Promising anticancer activities and mechanisms of action of active compounds from the medicinal herb Centipeda minima (L.) A. Braun &amp; Asch” [Phytomedicine 106 (2022) 154397]
Phytomedicine 2022cited by 0position: firstdoi
Pro-inflammatory and proliferative microglia drive progression of glioblastoma
Cell Reports 2021cited by 163position: middledoi
Phytochemical library screening reveals betulinic acid as a novel Skp2‐SCF E3 ligase inhibitor in non–small cell lung cancer
Cancer Science 2021cited by 23position: lastdoi
Centipeda minima extract sensitizes lung cancer cells to DNA-crosslinking agents via targeting Fanconi anemia pathway
Phytomedicine 2021cited by 22position: lastdoi
MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway
International Journal of Biological Sciences 2021cited by 18position: middledoi
Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma
Biochemical Pharmacology 2021cited by 8position: lastdoi
Acupoint catgut embedding improves senescence in a rat model of ageing by regulating mitophagy via the PINK1 pathway
Journal of Cellular and Molecular Medicine 2021cited by 7position: middledoi
Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals
Phytomedicine 2020cited by 248position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Dan‐Hua He · Guangzhou University of Chinese Medicine9 papers (2019–2023)Ming Hong · Guangzhou University of Chinese Medicine7 papers (2018–2025)Yong‐Xian Cheng · Shenzhen University6 papers (2019–2024)Pei‐En Wu · Guangzhou University of Chinese Medicine5 papers (2022–2025)Xiangzhen Fan · Guangzhou University of Chinese Medicine5 papers (2019–2023)Shi‐Bing Zhang · Guangzhou University of Chinese Medicine5 papers (2021–2023)Qi Wang · Hebei Medical University5 papers (2019–2021)Hailong Liu · Capital Medical University5 papers (2019–2024)Yun Bi · Weifang Medical University4 papers (2019–2021)Su-Fen Wei · Guangzhou University of Chinese Medicine4 papers (2019–2021)Huafeng Pan · Guangzhou University of Chinese Medicine4 papers (2019–2022)Jing Zhong · The First Affiliated Hospital, Sun Yat-sen University4 papers (2019–2021)Qi Wang · NSF NCAR High Altitude Observatory4 papers (2018–2021)Xianjun Yu · Hubei University of Medicine4 papers (2019–2021)Youliang Sun · Tsinghua University3 papers (2019–2021)Shifeng Fang · Dalian Medical University3 papers (2013–2022)Yan‐Chun Pang · Guangzhou University of Chinese Medicine3 papers (2023–2024)Da Huang · Guangzhou University of Chinese Medicine3 papers (2022–2023)Yile Zhou · Sun Yat-sen University3 papers (2019–2019)Qun Zhao · Suzhou University of Science and Technology3 papers (2019–2020)